Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 1.00 |
| ▸ | GSK3A | P49840 | 6/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 1/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 2/20 | 0.66 |
| ▸ | RGS4 | P49798 | 8/20 | 0.63 |
| ▸ | RGS8 | P57771 | 8/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023669 | 0.84 | GSK3A (0.73) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL5023665 | 0.84 | GSK3B (0.73) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL18802339 | 0.83 | GSK3B (0.71) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL6429448 | 0.83 | GSK3B (0.71) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL23763500 | 0.80 | GSK3B (0.77) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL5023670 | 0.80 | GSK3A (0.67) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL2107216 | 0.80 | GSK3B (1.00) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| Krm-7777 SCHEMBL3384141 | 0.79 | GSK3B (1.00) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL6427057 | 0.79 | GSK3A (0.65) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL18810378 | 0.79 | GSK3B (0.67) | GSK3BGSK3ACCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1658 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070916-A | Application of arteannuin with double functions in promoting liver cell maturation and relieving liver lipid metabolism dysfunction | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | 2026-05-22 | — | — | CN | claimed |
| CN-122060632-A | Weissella viridescens and application thereof in aspects of dispelling effects of alcohol, resisting inflammation and aging, reducing blood lipid and protecting liver | 广东药科大学 | 2026-05-19 | — | — | CN | claimed |
| WO-2025251988-A9 | REAGENT COMBINATION OR KIT FOR CONSTRUCTING EMBRYOID AND USE THEREOF | 广州国家实验室 | 2026-05-15 | — | — | WO | claimed |
| US-20260132380-A1 | Hepatocyte Expansion Methods | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-05-14 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12618045-B2 | Automated method for preparing retinal pigment epithelium cells | CENTRE D'ETUDE DES CELLULES SOUCHES (CECS) (FR) | 2026-05-05 | — | — | US | claimed |
| US-20260117173-A1 | METHOD FOR MESENCHYMAL PHENOTYPE REVERSION IN PRIMARY HUMAN CORNEAL ENDOTHELIAL CELLS | UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA (IT) | 2026-04-30 | — | — | US | claimed |
| US-20260108514-A1 | METHOD OF INHIBITING EPITHELIAL-MESENCHYMAL TRANSITION AND CANCER METASTASIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-04-23 | — | — | US | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| EP-2550355-A1 | DIRECTED DIFFERENTIATION AND MATURATION OF PLURIPOTENT CELLS INTO HEPATOCYTE LIKE CELLS BY MODULATION OF WNT-SIGNALLING PATHWAY | Cellartis AB (SE) | 2013-01-30 | — | — | EP | claimed |
| WO-2011151359-A1 | COMBINED TREATMENT WITH A CHOLINESTERASE INHIBITOR AND A THIADIAZOLIDINEDIONE DERIVATIVE | NOSCIRA, S.A. (ES) | 2011-12-08 | — | — | WO | claimed |
| WO-2011116930-A1 | DIRECTED DIFFERENTIATION AND MATURATION OF PLURIPOTENT CELLS INTO HEPATOCYTE LIKE CELLS BY MODULATION OF WNT-SIGNALLING PATHWAY | CELLARTIS AB (SE) | 2011-09-29 | — | — | WO | claimed |
| WO-2010108005-A2 | NOVEL NEURAL PROGENITORS FROM PLURIPOTENT STEM CELLS, METHODS OF PRODUCING SAME AND USE TO PRODUCE NEURAL CELLS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2010-09-23 | — | — | WO | claimed |
| US-20100166713-A1 | EARLY MESODERM CELLS, A STABLE POPULATION OF MESENDODERM CELLS THAT HAS UTILITY FOR GENERATION OF ENDODERM AND MESODERM LINEAGES AND MULTIPOTENT MIGRATORY CELLS (MMC) | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2010-07-01 | — | — | US | claimed |
| US-20100063109-A1 | THIADIAZOLIDINONE DERIVATIVES | UNIVERSITY OF ROCHESTER (US) | 2010-03-11 | — | — | US | claimed |
| EP-2126045-A2 | EARLY MESODERM CELLS, A STABLE POPULATION OF MESENDODERM CELLS THAT HAS UTILITY FOR GENERATION OF ENDODERM AND MESODERM LINEAGES AND MULTIPOTENT MIGRATORY CELLS (MMC) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008094597-A2 | EARLY MESODERM CELLS, A STABLE POPULATION OF MESENDODERM CELLS THAT HAS UTILITY FOR GENERATION OF ENDODERM AND MESODERM LINEAGES AND MULTIPOTENT MIGRATORY CELLS (MMC) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| US-20070196514-A1 | Prostate cancer treatment with glycogen synthase kinase-3beta inhibitors | UNIVERSITY OF KANSAS MEDICAL CENTER | 2007-08-23 | — | — | US | claimed |
| US-20060204980-A1 | Colorectal cancer therapies | MASSACHUSETTS, UNIVERSITY OF | 2006-09-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108514-A1 | METHOD OF INHIBITING EPITHELIAL-MESENCHYMAL TRANSITION AND CANCER METASTASIS | HDAC5, HDAC6, GSK3B | GSK3B 3/4885GSK3A 6/4885CCNB2 2309/4885 |
| US-12618045-B2 | Automated method for preparing retinal pigment epithelium cells | WNT3A, BRSK1, BMP2K | GSK3B 16/4885GSK3A 20/4885CCNB2 779/4885 |
| US-20260117173-A1 | METHOD FOR MESENCHYMAL PHENOTYPE REVERSION IN PRIMARY HUMAN CORNEAL ENDOTHELIAL CELLS | GSK3B, GSK3A, EPCAM | GSK3B 1/4885GSK3A 2/4885CCNB2 3824/4885 |
| US-20260132380-A1 | Hepatocyte Expansion Methods | HGF, CTNND1, MET | GSK3B 8/4885GSK3A 11/4885CCNB2 450/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | GSK3B 2/4885GSK3A 3/4885CCNB2 642/4885 |
| US-20100063109-A1 | THIADIAZOLIDINONE DERIVATIVES | IL5, PBK, MCL1 | GSK3B 1629/4885GSK3A 1960/4885CCNB2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.